Belgian Drugmaker in Talks on $800 Million Debt Deal

Belgian Drugmaker in Talks on $800 Million Debt Deal

Pharmaceuticals firm SERB plans to line up $800 million to finance an acquisition in the U.S. and may turn to direct lenders to fund part of the deal, according to three people with knowledge of the matter. The Brussels-based drug-maker, bought by private equity group...
Accel-KKR closes fifth fund since beginning of 2019

Accel-KKR closes fifth fund since beginning of 2019

Technology-focused private equity firm Accel-KKR has closed its latest fund, Accel-KKR Emerging Buyout Partners LP at USD640 million, bringing Accel-KKR’s total assets under management to over USD10 billion. “Despite the less-than-ideal conditions imposed by the...